Summary
Hikma Pharmaceuticals PLC (Hikma Pharmaceuticals) is a pharmaceutical manufacturing company. It undertakes the development, manufacturing and marketing of generic, branded and in-licensed patented products. Hikma Pharmaceuticals offers a wide range of products in the therapeutic areas of cardiovascular, CNS, diabetes, oncology, dermatology, genitourinary system, hormones and respiratory system, among others. It has partnerships with companies such as Astellas, Bio-Tech Pharmacal, Inc., Celltrion, Dong-A Pharm. Co.,Ltd., Edmond Pharma, Elpen Pharmaceutical company, Engelhard Arzneimittel and others. The company operates 27 manufacturing facilities in 11 countries and has presence in 50 countries across the Middle East and North Africa region, the US and Europe. Hikma Pharmaceuticals is headquartered in London, the UK.The company focuses on strengthening and broadening its product portfolio. In line with this the company entered into an exclusive license agreement with Azanta A/S for having the exclusive rights to its proprietary cancer product Nimoral.
Hikma Pharmaceuticals Plc (HIK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
Hikma Pharmaceuticals Plc, Medical Devices Deals, 2010 to YTD 2016 12
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 13
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
West-Ward Pharma Acquires The US Generic Injectables Business From Baxter Healthcare For US$112 Million 16
Hikma Pharma Acquires Multi-Source Injectables Business From Baxter Healthcare For US$112 Million 18
Partnerships 20
Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 20
Hikma Pharma Enters Into Co-Development Agreement With AUB-NCC For Anticancer Drugs 21
Hikma Pharma Forms Joint Venture With Midroc Pharma 22
Venture Life Enters into Distribution Agreement with Hikma Pharma 23
Hikma Pharma Enters Into Co-Promotion Agreement With Therabel Pharma For Loramyc 24
Hikma Pharma Enters Into An Agreement With Celltrion And Celltrion Healthcare 25
BioCryst Pharma Enters Into Co-Marketing Agreement With Hikma Pharma 26
Licensing Agreements 28
Hikma Pharma Enters into Licensing Agreement with Basilea Pharma 28
Hikma Pharma Enters into Licensing Agreement with Vitabiotics 29
Hikma Pharma Enters into Licensing Agreement with Azanta 30
Hikma Pharma Enters into Licensing Agreement with SK Chemicals 31
Hikma Pharma Enters into Licensing and Supply Agreement with GP Pharm 32
Hikma Pharma Enters Into Licensing Agreement With Theravance For Vibativ 33
Hikma Pharma Enters Into Licensing Agreement With Dance Biopharm For Inhaled Insulin Product 35
Sinclair IS Pharma Enters Into Licensing Agreement With Hikma Pharma For Flammacerium 36
Hikma Pharma Enters Into Licensing Agreement With EffRx Pharma For Binosto 37
Hikma Pharma Enters Into Licensing Agreement With GP Pharm For Lutrate 1 Month 38
AEterna Zentaris Enters Into Licensing Agreement With Hikma Pharma For Perifosine 39
Hikma Pharma Enters Into Licensing Agreement With Vifor Pharma For Ferinject 41
Debt Offering 43
Hikma Pharma Prices Private Placement of Bonds Due 2020 for USD500 Million 43
Asset Transactions 44
Renaissance Pharma Plans to Acquire Assets of Two Generic Drugs from Hikma Pharma 44
Unimark Remedies Plans to Acquire US Marketing Rights to Flecainide from Hikma Pharma 45
Hikma Pharma Terminates Divestiture Of Its Injectables Business 46
X-Gen Pharma Acquires Phenytoin and Promethazine from Hikma Pharma 47
Acquisition 48
Hikma Pharma Acquires Roxane Labs and Boehringer Ingelheim Roxane from Boehringer Ingelheim Pharma 48
Hikma Pharma to Acquire EIMC United Pharma 51
Boehringer Ingelheim May Sell Roxane Labs 52
Hikma Pharma Completes Acquisition of Bedford Labs from Ben Venue Labs for USD300 Million 53
Hikma Pharma Plans To Acquire Pharma Company In Middle East And Africa 55
Hikma Pharm Acquires Egyptian Company for Pharma & Chemical for USD22 Million 56
Hikma Pharma Completes Acquisition Of Additional 30.2% Stake In Promopharm For US$42 Million 58
Hikma Pharma Acquires 63.9% Stake In Promopharm For US$111 Million 59
Hikma Pharma Acquires Minority Stake In Hubei Haosun 61
Hikma Pharma Completes Acquisition Of 23.1% Stake In Unimark Remedies For US$34 Million 62
Arab Pharma Manufacturing Acquires Remaining 50% Joint Venture Stake In Al Dar Al Arabia From Dar Al Dawa Development 64
Hikma Acquires Additional Stake In Industries Pharmaceutiques Ibn Al Baytar 66
Hikma Pharmaceuticals Plc - Key Competitors 67
Key Employees 68
Locations And Subsidiaries 69
Head Office 69
Other Locations & Subsidiaries 69
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72
List of Tables
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2014 1
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Hikma Pharmaceuticals Plc, Deals By Therapy Area, 2010 to YTD 2016 10
Hikma Pharmaceuticals Plc, Medical Devices Deals, 2010 to YTD 2016 12
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 13
West-Ward Pharma Acquires The US Generic Injectables Business From Baxter Healthcare For US$112 Million 16
Hikma Pharma Acquires Multi-Source Injectables Business From Baxter Healthcare For US$112 Million 18
Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 20
Hikma Pharma Enters Into Co-Development Agreement With AUB-NCC For Anticancer Drugs 21
Hikma Pharma Forms Joint Venture With Midroc Pharma 22
Venture Life Enters into Distribution Agreement with Hikma Pharma 23
Hikma Pharma Enters Into Co-Promotion Agreement With Therabel Pharma For Loramyc 24
Hikma Pharma Enters Into An Agreement With Celltrion And Celltrion Healthcare 25
BioCryst Pharma Enters Into Co-Marketing Agreement With Hikma Pharma 26
Hikma Pharma Enters into Licensing Agreement with Basilea Pharma 28
Hikma Pharma Enters into Licensing Agreement with Vitabiotics 29
Hikma Pharma Enters into Licensing Agreement with Azanta 30
Hikma Pharma Enters into Licensing Agreement with SK Chemicals 31
Hikma Pharma Enters into Licensing and Supply Agreement with GP Pharm 32
Hikma Pharma Enters Into Licensing Agreement With Theravance For Vibativ 33
Hikma Pharma Enters Into Licensing Agreement With Dance Biopharm For Inhaled Insulin Product 35
Sinclair IS Pharma Enters Into Licensing Agreement With Hikma Pharma For Flammacerium 36
Hikma Pharma Enters Into Licensing Agreement With EffRx Pharma For Binosto 37
Hikma Pharma Enters Into Licensing Agreement With GP Pharm For Lutrate 1 Month 38
AEterna Zentaris Enters Into Licensing Agreement With Hikma Pharma For Perifosine 39
Hikma Pharma Enters Into Licensing Agreement With Vifor Pharma For Ferinject 41
Hikma Pharma Prices Private Placement of Bonds Due 2020 for USD500 Million 43
Renaissance Pharma Plans to Acquire Assets of Two Generic Drugs from Hikma Pharma 44
Unimark Remedies Plans to Acquire US Marketing Rights to Flecainide from Hikma Pharma 45
Hikma Pharma Terminates Divestiture Of Its Injectables Business 46
X-Gen Pharma Acquires Phenytoin and Promethazine from Hikma Pharma 47
Hikma Pharma Acquires Roxane Labs and Boehringer Ingelheim Roxane from Boehringer Ingelheim Pharma 48
Hikma Pharma to Acquire EIMC United Pharma 51
Boehringer Ingelheim May Sell Roxane Labs 52
Hikma Pharma Completes Acquisition of Bedford Labs from Ben Venue Labs for USD300 Million 53
Hikma Pharma Plans To Acquire Pharma Company In Middle East And Africa 55
Hikma Pharm Acquires Egyptian Company for Pharma & Chemical for USD22 Million 56
Hikma Pharma Completes Acquisition Of Additional 30.2% Stake In Promopharm For US$42 Million 58
Hikma Pharma Acquires 63.9% Stake In Promopharm For US$111 Million 59
Hikma Pharma Acquires Minority Stake In Hubei Haosun 61
Hikma Pharma Completes Acquisition Of 23.1% Stake In Unimark Remedies For US$34 Million 62
Arab Pharma Manufacturing Acquires Remaining 50% Joint Venture Stake In Al Dar Al Arabia From Dar Al Dawa Development 64
Hikma Acquires Additional Stake In Industries Pharmaceutiques Ibn Al Baytar 66
Hikma Pharmaceuticals Plc, Key Competitors 67
Hikma Pharmaceuticals Plc, Key Employees 68
Hikma Pharmaceuticals Plc, Subsidiaries 69
List of Figures
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 8
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
Hikma Pharmaceuticals Plc, Medical Devices Deals, 2010 to YTD 2016 12
